Form 4: Director Andrew C. von Eschenbach Acquires BLCO Shares

Director Andrew C. von Eschenbach received an annual grant of 15,842 restricted share units in Bausch + Lomb Corporation.

Summary

• Director Andrew C. von Eschenbach acquired 15,842 common shares of Bausch + Lomb Corporation (BLCO).
• The acquisition was part of an annual grant of restricted share units (RSUs) to non-employee directors.
• The transaction was valued at $15.78 per share.
• Following this transaction, the director's total beneficial ownership is 86,656 common shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Director alignment with shareholder interests through equity-based compensation.
• Standard annual equity grant indicates stable corporate governance practices.

Negatives

• None identified.

Risks

• Market price volatility affecting the value of equity holdings.

Future Outlook

The RSUs are scheduled to vest on the date immediately preceding the conclusion of the next annual meeting of shareholders.

Industry Context

StockSavvy.ai notes that annual equity grants to non-employee directors are a standard corporate governance practice in the pharmaceutical and medical device industry to ensure long-term alignment between board members and shareholders.

Comparison to Industry Standards

• The use of the 2022 Omnibus Incentive Plan for director compensation is consistent with standard practices for large-cap healthcare companies.
• The vesting schedule tied to the annual meeting is a common industry benchmark for director equity retention.

Corporate Governance

Stakeholder Impact

• Shareholders: Increased alignment between board members and company performance.

Next Steps

• Vesting of the granted RSUs prior to the next annual meeting of shareholders.

Key Dates

Keywords

Bausch + Lomb, BLCO, Insider Trading, Form 4, Director Compensation, Equity Grant